Mereo BioPharma Group plc (NasdaqCM: MREO)
Health Care · Biotechnology · GB
$0.28
-3.58% today · -82.9% 1Y
Mereo BioPharma Group plc (NasdaqCM: MREO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $46.37M and employs 39 people.
Over the last twelve months the share price has lost 82.9%, trading between 0.20 and 2.37.
Tweenvest scores Mereo BioPharma Group plc across four factors: quality 27/100. Its strongest factor is quality.
MREO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $46.37M
- Revenue (TTM)
- $0.00
- P/E
- —
- EPS
- -0.18
- Dividend yield
- —
- Beta (5Y)
- 0.30
- 52-week high
- $2.37
- 52-week low
- $0.20
- Avg volume (3M)
- —
- Shares outstanding
- 159.69M
- Employees
- 39
- Next earnings
- —
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.
- ISIN
- US5894921072
- Founded
- 2015
- Listed since
- Apr 24, 2019
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.75 | +0.55% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.61 | +0.34% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.00 | -1.43% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.